Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Range Resources Corporation Common Stock (RRC) vs 10X Genomics Inc (TXG) Price & Performance

Range Resources Corporation Common StockTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Range Resources Corporation Common Stock vs 10X Genomics Inc — how do they compare? Range Resources Corporation Common Stock trades at $41.78 (market cap $9.93B), while 10X Genomics Inc trades at $71.65 (market cap $9.35B). The key difference: Range Resources Corporation Common Stock and 10X Genomics Inc are close in size by market cap, and Range Resources Corporation Common Stock pays a 0.94% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Range Resources Corporation Common Stock for 0 Days and 10X Genomics Inc for 91 Days on average.

RRCTXG
Market Cap
$9.93B$9.35B
Volume
2,413,7524,039,449
Sector
EnergyHealth
52-Week High
$47.65$97.74
52-Week Low
$33.43$11.83
Typical Hold Time
0 Days91 Days
Enterprise Value
$10.94B$8.88B
Dividend Yield
0.94%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Range Resources Corporation Common Stock

Range Resources (RRC) trades at $42.48, up 2.56% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows solid fundamentals with a P/E of 11.73 and net income margin of 26.32%, while technical indicators signal neutral momentum near key resistance at $43. Recent institutional buying and positive analyst coverage (38.71% buy ratings) support the bullish case.

Outlook remains positive with Q3 2026 earnings expected at $0.776 per share and consensus price target of $44.00 offering 3.6% upside. Risks include energy price volatility and negative net cash flow of -$304M in 2025, though improved 2026 projections show operating cash flow growth to $1.4B.

10X Genomics Inc

TXG trades at $73.10, down 2.78% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $642.82M in 2025 but a net loss of $43.54M, though recent quarters show earnings beats. Analyst consensus is mixed with a $83.30 price target. Positive news includes Atera shipments and a patent victory, but profitability remains a challenge.

The outlook hinges on Atera's commercial success driving future revenue growth and margin improvement. Risks include persistent losses, competitive pressures, and execution delays. Upside potential exists if new platforms gain traction, but investors should weigh high valuation multiples against ongoing unprofitability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RRC
100% Buy0% Sell
Avg holding period · 0 Days
TXG
17% Buy83% Sell
Avg holding period · 91 Days

Top news

Latest headlines on both assets

About Range Resources Corporation Common Stock

Range Resources Corporation is an independent natural gas and natural gas liquids producer operating in the Appalachian Basin, primarily the Marcellus Shale in Pennsylvania, handling drilling, completion, and gathering and transportation connections for its production.

Read more on RRC →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →